Cyclerion Therapeutics, Inc. Operating Income Loss

• Cyclerion Therapeutics, Inc. showed a decrease of -37.1% in Operating Income Loss from 2024 to 2025.
• This data is from Cyclerion Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
• XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 8 years of available data (2018 to 2025), Cyclerion Therapeutics, Inc.'s Operating Income Loss has grown by 95.7%.
• Historical annual values: Fiscal year 2025: -$4.97 million | Fiscal year 2024: -$3.63 million | Fiscal year 2023: -$12.95 million | Fiscal year 2022: -$18.54 million | Fiscal year 2021: -$55.20 million | Fiscal year 2020: -$81.27 million | Fiscal year 2019: -$125.04 million | Fiscal year 2018: -$115.25 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026